O2 Proteome-based classification of non-muscle invasive bladder cancer

By: Fragkoulis C.¹, Stroggilos R.², Latosinska A.³, Makridakis M.², Lygirou V.², Mavrogeorgis E.⁴, Drekolas D.⁵, Frantzis M.³, Mullen W.⁶, Stasinopoulos K.¹, Papadopoulos G.¹, Stathouros G.¹, Lazaris A.⁶, Makrythanasis P.², Ntoumas K.¹, Mischak H.³, Zoidakis J.², Vlahou A.²

¹General Hospital of Athens, Dept. of Urology, Athens, Greece, ²Biomedical Research Foundation of the Academy of Athens, Dept. of Biotechnology, Athens, Greece, ³Mosaiques Diagnostics GmbH, Mosaiques Diagnostics, Hannover, Germany, ⁴Agricultural University of Athens, Dept. of Biotechnology, Athens, Greece, ⁵Medical School of Athens, Dept. of Pathology, Athens, Greece, ⁶British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

O3 The Phoenix criteria for biochemically recurrent prostate cancer after curative radiotherapy appear obsolete in the era of prostate-specific membrane antigen PET: A plea for urgent re-evaluation of current guidelines

By: Jansen B.H.E.¹, Van Leeuwen P.², Wondergem M.³, Van Der Sluis T.¹, Nieuwenhuijzen J.¹, Knol R.³, Van Mooreselaar J.¹, Van Der Poel H.², Oprea-Lager D.⁴, Vis A.¹

¹Vrije Universiteit, Dept. of Urology, Amsterdam, The Netherlands, ²Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³Noordwest Groep, Dept. of Nuclear Medicine, Alkmaar, The Netherlands, ⁴Vrije Universiteit, Dept. of Radiology and Nuclear Medicine, Amsterdam, The Netherlands

O4 Micro-ultrasound versus multiparametric MRI in the detection of prostate cancer: Results from a prospective single center trial

By: Maffei D.¹, Paciotti M.¹, Lazzeri M.¹, Frego N.¹, Fasulo V.¹, Diana P.¹, Regis F.¹, Elefante G.M.², Colombo P.², Saita A.R.¹, Hurle R.¹, Casale P.¹, Buffi N.M.³, Guazzoni G.F.³, Lughezzani G.³

¹Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, ²Humanitas Clinical and Research Center, Dept. of Anatomopathology, Rozzano, Italy, ³Humanitas University, Dept. of Urology, Rozzano, Italy
Safety of abiraterone and enzalutamide in prostate cancer patients treated with anticoagulants

By: Goena Vives M.C.1, Rilo I.2, García R.1, Mañas L.1, Beramendi J.R.2, Quintas L.1
1Mendaro Hospital, Dept. of Cardiology, Mendaro, Spain, 2Donostia University Hospital, Dept. of Cardiology, San Sebastian, Spain

Patient-reported outcomes (PROs) from TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic Castration-Sensitive Prostate Cancer (mCSPC)

1University of Utah, Huntsman Cancer Institute, Salt Lake City, United States of America, 2Janssen Research & Development, Strategic Market Access, Horsham, United States of America, 3Skåne University Hospital, Lund University, Malmo, Sweden, 4Guy’s, King’s, and St Thomas’ Hospitals and Sarah Cannon Research Institute, Dept. of Medical Oncology, London, United Kingdom, 5Liga Norte Riograndense Contra O Cancer, Dept. of Oncology, Natal, Brazil, 6Yonsei University College of Medicine and Gangnam Severance Hospital, Dept. of Urology, Seoul, South Korea, 7Istanbul University-Cerrahpaşa, Dept. of Oncology, Istanbul, Turkey, 8Hospital Universitario de Jerez de la Frontera, Dept. of Urology, Cadiz, Spain, 9University Hospital Schleswig-Holstein, Dept. of Urology, Lübeck, Germany, 10Kindai University Faculty of Medicine, Dept. of Urology, Osaka, Japan, 11Fudan University, Shanghai Cancer Center, Dept. of Urology, Shanghai, China, 12Eastern Virginia Medical School, Dept. of Urology, Norfolk, United States of America, 13Janssen Research & Development, Clinical Biostats, San Diego, United States of America, 14Janssen Global Services, Global Market Access, Raritan, United States of America, 15Janssen Research & Development, Dept. of Oncology, Beerse, Belgium, 16Janssen Research & Development, Dept. of Oncology, San Diego, United States of America, 17Janssen Research & Development, Dept. of Oncology, Los Angeles, United States of America, 18BC Cancer, Dept. of Medicine, Vancouver, Canada